Therefore, the RIP1 kinase-RIP3 kinase-MLKL-axis may serve as a potential target of small-molecule therapeutics by inhibiting pro-necroptotic pathway in the treatment of NAFL/NASH. This evidence concerns the gene MLKL and metabolic dysfunction-associated steatohepatitis.